
==== Front
Trials
Trials
Trials
1745-6215
BioMed Central London

8146
10.1186/s13063-024-08146-1
Correction
Correction: Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET
Singh Simron 1
Ferone Diego 2
Capdevila Jaume 3
Chan Jennifer Ang 4
de Herder Wouter W. 5
Halperin Daniel 6
Mailman Josh 7
Hellström Lisa 8
Liedman Hanna 8
Svedberg Agneta 8
Tiberg Fredrik Fredrik.Tiberg@camurus.com

8
1 https://ror.org/03wefcv03 grid.413104.3 0000 0000 9743 1587 Sunnybrook Health Sciences Center, Toronto, Canada
2 grid.5606.5 0000 0001 2151 3065 Endocrinology, Department of Internal Medicine & Medical Specialties, University of Genova, Endocrinology Clinic IRCCS Ospedale Policlinico San Martino, Genoa, Italy
3 grid.411083.f 0000 0001 0675 8654 Vall d’Hebron University Hospital, Barcelona, Spain
4 https://ror.org/02jzgtq86 grid.65499.37 0000 0001 2106 9910 Dana-Farber Cancer Institute, Boston, MA USA
5 grid.508717.c 0000 0004 0637 3764 Erasmus MC & Erasmus MC Cancer Institute, Rotterdam, The Netherlands
6 https://ror.org/04twxam07 grid.240145.6 0000 0001 2291 4776 The University of Texas MD Anderson Cancer Center, Houston, TX USA
7 Northern California CarciNET Community, Oakland, CA USA
8 grid.476205.2 Camurus AB, Lund, Sweden
2 5 2024
2 5 2024
2024
25 297© The Author(s) 2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmc Correction: Trials 25, 58 (2024)

https://doi.org/10.1186/s13063-023-07834-8

Following publication of the original article [1], we have been notified that a correction is needed on page 3, paragraph 2 as shown below:

Incorrect statement: “Additionally, CAM2029 administration can be undertaken by the patient or carer themselves using a pre-filled pen, whereas administration of both octreotide LAR and lanreotide ATG requires medical assistance.”

Correct statement: “Additionally, CAM2029 administration can be undertaken by the patient or carer themselves using a pre-filled pen, whereas administration of octreotide LAR requires medical assistance. For patients who receive a stable dose of lanreotide ATG, the product can be administered either by the patient or by a trained person (Reference Somatuline Autogel 60 mg, solution for injection in a prefilled syringe—Summary of Product Characteristics (SmPC)—(emc) (medicines.org.uk)).”

The original article has been corrected.
==== Refs
Reference

1. Singh S Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET Trials 2024 25 58 10.1186/s13063-023-07834-8 38229199
